168 related articles for article (PubMed ID: 2444606)
1. Production of platelet-derived growth factor by cultured Wilms' tumor cells and fetal kidney cells.
Fraizer GE; Bowen-Pope DF; Vogel AM
J Cell Physiol; 1987 Oct; 133(1):169-74. PubMed ID: 2444606
[TBL] [Abstract][Full Text] [Related]
2. Expression of the PAX2 gene in human fetal kidney and Wilms' tumor.
Eccles MR; Wallis LJ; Fidler AE; Spurr NK; Goodfellow PJ; Reeve AE
Cell Growth Differ; 1992 May; 3(5):279-89. PubMed ID: 1378753
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
Yun K; Fidler AE; Eccles MR; Reeve AE
Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
[TBL] [Abstract][Full Text] [Related]
4. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the inability to sustain growth in defined serum-free medium with the suppression of tumorigenicity in Wilms' nephroblastoma.
Dowdy SF; Weissman BE; Stanbridge EJ
J Cell Physiol; 1991 May; 147(2):248-55. PubMed ID: 1645741
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumorigenicity of a Wilms' tumor cell line is associated with a decrease in synthesis of two proteins.
Wheeler TT; Xiao JP; Dowdy SF; Stanbridge EJ; Young DA
Oncogene; 1991 Oct; 6(10):1903-7. PubMed ID: 1656366
[TBL] [Abstract][Full Text] [Related]
7. The chromosome 11 region flanking the t(11;14) breakpoint in human T-ALL is deleted in Wilms' tumor hybrids.
Finver SN; Martiniere C; Kagan J; Cavenee W; Croce CM
Oncogene Res; 1989; 5(2):143-8. PubMed ID: 2558334
[TBL] [Abstract][Full Text] [Related]
8. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells.
Potapova O; Fakhrai H; Baird S; Mercola D
Cancer Res; 1996 Jan; 56(2):280-6. PubMed ID: 8542581
[TBL] [Abstract][Full Text] [Related]
9. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
10. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
Vu TH; Chuyen NV; Li T; Hoffman AR
Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
[TBL] [Abstract][Full Text] [Related]
11. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor.
Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ
Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318
[TBL] [Abstract][Full Text] [Related]
12. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney.
Garvin AJ; Re GG; Tarnowski BI; Hazen-Martin DJ; Sens DA
Am J Pathol; 1993 Feb; 142(2):375-80. PubMed ID: 8382007
[TBL] [Abstract][Full Text] [Related]
13. Aberrant imprinting of the insulin-like growth factor II receptor gene in Wilms' tumor.
Xu YQ; Grundy P; Polychronakos C
Oncogene; 1997 Mar; 14(9):1041-6. PubMed ID: 9070652
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
Abramson LP; Stellmach V; Doll JA; Cornwell M; Arensman RM; Crawford SE
J Pediatr Surg; 2003 Mar; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
[TBL] [Abstract][Full Text] [Related]
15. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
17. WT1 expression alters tumorigenicity of the G401 kidney-derived cell line.
McMaster ML; Gessler M; Stanbridge EJ; Weissman BE
Cell Growth Differ; 1995 Dec; 6(12):1609-17. PubMed ID: 9019166
[TBL] [Abstract][Full Text] [Related]
18. Chromosome analysis of 31 Wilms' tumors.
Sheng WW; Soukup S; Bove K; Gotwals B; Lampkin B
Cancer Res; 1990 May; 50(9):2786-93. PubMed ID: 2158398
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
